and well-being of children and youth
The Canadian Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our copyright policy.
Children with acute asthma exacerbations frequently present to an emergency department with signs of respiratory distress. The most severe episodes are potentially life-threatening. Effective treatment depends on the accurate and rapid assessment of disease severity at presentation. This statement addresses the assessment, management and disposition of paediatric patients with a known diagnosis of asthma who present with an acute asthma exacerbation, especially preschoolers at high risk for persistent asthma. Guidance includes the assessment of asthma severity, treatment considerations, proper discharge planning, follow-up, and prescription for inhaled corticosteroids to prevent exacerbation and decrease chronic morbidity.
Key Words: Asthma; Disposition; Emergency management; Paediatrics; Preschoolers
Asthma is a common, chronic inflammatory disorder of the airways associated with airway hyper-responsiveness. Asthma exacerbations are the leading cause of hospitalization in children , and the lifetime prevalence of asthma in Canadian children has been estimated at 11% to 16% .
For this statement, asthma exacerbation is defined as an acute or subacute deterioration of symptom control that causes distress or risks health to the extent that a visit to a health care provider or treatment with systemic corticosteroids becomes necessary . The most common triggers for asthma exacerbations in both younger and older children are viral respiratory tract infections; other typical factors are exposure to allergens and a suboptimal control of asthma as a baseline . Acute exacerbations are a frequent cause of emergency department (ED) visits . Guttmann and colleagues  reported that in Ontario, over 9% of children with asthma had made at least one ED visit in the past two years, and asthma exacerbations accounted for 3% to 7% of all paediatric ED visits. More than 50% of children who present to the ED with an asthma exacerbation are preschool age (<5 years) (5). Rosychuk et al  recently reported that in Alberta, nearly 10% of the paediatric ED visits resulted in an admission to hospital, with one death for every 25,000 ED visits.
Many health care centres across Canada and a wide range of national and international health organizations have developed their own practice guidelines for the assessment and management of acute asthma exacerbations -. The use of evidence-based asthma guidelines can improve outcomes for children with asthma . This statement specifically addresses the ED management of acute asthma exacerbations in paediatric patients with a known diagnosis of asthma, particularly preschoolers with early transient wheezing whose pattern of symptoms and history of atopy suggest a high risk for persistent asthma .
Classification of asthma severity
|Clinical features||Mild||Moderate||Severe||Impending respiratory failure|
|Mental status||Normal||Might look agitated||Usually agitated||Drowsy or confused|
|Activity||Normal activity and exertional dyspnea||Decreased activity or feeding (infant)||Decreased activity infant, stops feeding||Unable to eat|
|Speech||Normal||Speaks in phrases||Speaks in words||Unable to speak|
|Work of breathing||Minimal intercostal retractions||Intercostal and substernal retractions||Significant respiratory distress. Usually all accessory muscles involved, and may display nasal flaring and paradoxical thoraco-abdominal movement||Marked respiratory distress at rest. All accessory muscles involved, including nasal flaring and paradoxical thoraco-abdominal movement|
|Chest auscultation||Moderate wheeze||Loud pan-expiratory and inspiratory wheeze||Wheezes might be audible without stethoscope||The chest is silent (absence of wheeze)|
|SpO2 on room air||>94%||91–94%||<90%|
|Peak flow versus personal best||>80%||60–80%||best <60%||Unable to perform the task|
|Definitions are not absolute and can overlap. The presence of several parameters indicates the classification of the exacerbation.|
Assessment should include:
After conducting the initial assessment, a treating physician should categorize disease severity. There are different clinical tools for assessing disease severity in patients with acute asthma exacerbation -. Birken et al  compared the performance of various assessment tools  and concluded that the Clinical Assessment Score  and the Pediatric Respiratory Assessment Measure (PRAM)  both reliably assess the severity of an acute asthma exacerbation and are sensitive to changes in clinical status. Typically, clinical tools take into consideration many of the following parameters: level of alertness, ability to speak in full sentences, use of accessory muscles, air entry in both lungs, presence of wheezing and O2 saturation (Table 1).
Independent of the method of assessment, the same parameters used to estimate disease severity at baseline should be used after each treatment, on a regular basis, and at discharge.
2. Medical management steps
Patients who are acutely distressed, have signs of severe respiratory impairment or show signs of impending respiratory failure (eg, altered level of consciousness, silent chest, central cyanosis) should be treated immediately with oxygen and short-acting bronchodilators . Anaphylaxis can present with severe respiratory distress that mimics a severe asthma attack . If anaphylaxis is suspected, treat immediately with epinephrine.
Otherwise, treatment should be instituted as soon as the assessment is completed. Patients should then be monitored closely to assess their response to initial management and to ensure proper care and disposition after the acute episode.
The flow diagram (Figure 1) shows a pathway to assess and treat children with asthma exacerbation.
Oxygen: Hypoxemia (SpO2 <92%) must be treated urgently with oxygen delivered by face mask or nasal canulae. There is no strong evidence in support of a specific goal for SpO2. In the context of acute respiratory distress, a SpO2 ≥94% appears reasonable .
Short-acting ß2-agonists: Salbutamol (albuterol) is the bronchodilator of choice . A metered-dose inhaler (MDI) with a spacer is the preferred device for salbutamol administration because it is more efficient than a nebulizer for bronchodilator delivery (22]. An MDI can be used in almost all situations except for very severe episodes with impending respiratory failure. Even in the presence of hypoxemia, oxygen can be given by nasal canulae at the same time that salbutamol is given by MDI and spacer. In children without initial oxygen requirements, ß2-agonists administered by MDI and spacer are less likely to provoke hypoxemia and tachycardia than a nebulizer .
The recommended doses for MDI and nebulizer ß2-agonists delivery are listed in Table 2. The dose and frequency of intermittent salbutamol therapy depend on the severity of an acute attack and the patient’s response to treatment. The first dose of salbutamol should be given as soon as possible after rapid triage and evaluation in the ED. In patients having a severe asthma attack, the continuous administration of nebulized ß2-agonists may have a better and more prolonged bronchodilator effect compared with intermittent therapy . Side effects of salbutamol include tachycardia, hyperglycemia and hypokalemia, which are generally well tolerated. There is no evidence in the paediatric age group of reversible arrhythmias following treatment with ß2-agonists, but this side effect has been reported in adults. Paediatric patients treated with continuous nebulized ß2-agonists should be monitored for cardiac arrhythmias.
Medications and dosages for acute asthma treatment as per disease severity
Drug and route
See discharge plan and Table 3
<20 kg = 5 puffs (0.1 mg/puff),
5 mg in 2 ml of normal saline to be given every 20 min during the first h
Monitor potassium serum levels in patients requiring frequent doses
prednisone or prednisolone
Prolonged course or frequently repeated doses can be associated with adrenal suppression
Start treatment early. Recommended as one single dose in the morning to decrease risk of adrenal suppression
Puffs (20 µg) every 20 min x 3 doses
Use with caution in children with soy allergy
Tachycardia, hypokalemia, hyperglycemia
Monitor heart rhythm and rate, glucose and electrolytes
<20 kg = 0.25 mg,
Can be mixed with salbutamol aerosols
IV magnesium sulfate
25–50 mg/kg IV bolus over 20 min (maximum 2 g)
Consider if patient is not improving
Severe to impending respiratory failure
Load: 7.5 mcg/kg over
Tachycardia, hypokalemia, hyperglycemia
Monitor heart rhythm and rate, glucose and electrolytes
|* Conventional treatment: Oral corticosteroids, nebulized salbutamol ± ipratropium|
† Maximized treatment: IV steroids, continuous nebulized salbutamol + ipratropium
MDI = metered dose inhaler
Inhaled anticholinergics: Inhaled ipratropium bromide can be used as an add-on therapy to ß2-agonists. Some randomized control trials demonstrated reduced hospital admission rates and better lung function when ß2-agonists were used in combination with inhaled ipratropium during the first hour, compared with ß2-agonists used alone . The dose may be repeated every 20 min for the first hour, mixed with ß2-agonists. There are no clinical trials supporting ipratropium use beyond the first hour in children.
Oral/intravenous (IV) corticosteroids: Children who have a moderate to severe asthma exacerbation should receive systemic steroids as part of their initial treatment. This medication should be administered as early in the ED visit as feasible. Steroids may reduce the need for hospitalization and the risk of relapse after initial treatment, and may also facilitate an earlier discharge from the hospital . The recommended doses of corticosteroids are listed in Table 2. Children with severe asthma or impending respiratory failure should receive IV steroids. The drugs of choice are methylprednisolone and hydrocortisone.
Magnesium sulphate: A recent meta-analysis suggested that IV magnesium sulphate may be effective in children with severe acute asthma, improving respiratory function and decreasing hospital admissions . IV magnesium sulphate may be considered in cases of moderate and severe asthma with incomplete response to conventional therapy during the first 1 to 2 h . Patients treated with magnesium sulphate can have hypotension and bradycardia as side effects, and their vital signs should be monitored during treatment. Consultation with an intensive care unit (ICU) physician or respirologist is recommended.
IV salbutamol infusion: This delivery method should be used in patients with severe asthma who do not respond to other treatments . In patients with severe attacks, IV ß2-agonists have been shown to improve pulmonary function and gas exchange . In general, inhaled drugs may have a limited effect in patients with nearly complete airway obstruction and have practical limitations in ventilated patients. Cardiac responses, such as arrhythmia and tachycardia, are significant side effects of this medication. Patients receiving IV salbutamol should be in a setting where continuous cardiac monitoring is available.
IV aminophylline: This bronchodilator is reserved for children in the ICU setting with a severe asthma exacerbation who have failed to improve despite maximized therapy (continuous inhaled ß2-agonists, IV corticosteroids) .
Heliox: Using a helium-oxygen gas mixture is reserved for children in the ICU setting with severe asthma exacerbation who have failed to improve despite maximized therapy .
Endotracheal intubation and ventilation for impending respiratory failure:
Intubation and mechanical ventilation can be life-saving interventions but their use in paediatric patients with asthma have been associated with significant adverse effects. Up to 26% of children intubated due to asthma have complications, such as pneumothorax or impaired venous return, and cardiovascular collapse because of increased intrathoracic pressure . Mechanical ventilation during an asthma exacerbation is associated with increased risk of death and should be considered as a last resort and only in conjunction with the support of a paediatric ICU specialist.
Admission should be considered if any one of the following apply:
Other criteria may also be taken into consideration (eg, distance from home, comorbid conditions such as anaphylaxis).
ICU admission or referral to a tertiary care centre should be considered if:
Discharge criteria from the ED include:
Children with persistent asthma and/or who have a moderate or severe episode should be given inhaled corticosteroids (ICS) on a regular basis. If the patient is already taking ICS, the dose should be reviewed and adjusted . ICS are the cornerstone of regular preventive anti-inflammatory treatment to protect against exacerbations and chronic morbidity. The literature does not support a role for short-term intermittent therapy. ICS in appropriate doses are safe and efficacious. Long-term studies have demonstrated that ICS use does not impair growth or affect final adult height. Although there is a potential risk for adrenal suppression when high doses of ICS are used over prolonged periods, this risk can be diminished with proper monitoring and the use of newer ICS. Common ICS and doses are listed in Tables 3 and 4 .
Inhaled corticosteroid (ICS) dosing categories in paediatrics
Daily inhaled corticosteroid dose, µg
(6 to 11 years of age)
(12 years of age and over)
Beclomethasone dipropionate HFA
Flovent MDI and spacer; Flovent Diskus¶
Note: Dose equivalencies are approximate and are based on efficacy data. Categories are somewhat arbitrary but are based on manufacturers’ recommendations.
Starting doses for inhaled corticosteroids for asthma therapy in children in Canada*
Medication and inhaler device
Minimum age licensed for use in Canada
Low to moderate dose
Beclomethasone–hydrofluoroalkane by metered-dose inhaler and spacer
100–150 µg twice daily
200 µg twice daily
Budesonide by dry powder inhaler
200 µg twice daily
400 µg twice daily
Budesonide by wet nebulizer†
250–500 µg twice daily
1000 µg twice daily
Fluticasone by metered-dose inhaler and spacer or dry powder inhaler
100–125 µg twice daily
250 µg twice daily
Ciclesonide by metered-dose inhaler and spacer
100–200 µg once daily
400 µg once or twice daily§
|*Adapted from the Canadian asthma consensus report (1999). †It is preferable to administer high-dose inhaled corticosteroids (or budesonide by nebulizer) in consultation with an asthma expert.|
‡The youngest children able to use a dry powder inhaler are generally 4 to 5 years of age (11).
§Ciclesonide is usually used once daily except in cases of more severe disease.
Source: Kovesi T, Schuh S, Spier S et al. Case-based asthma Guidelines adaptation for the management of preschoolers with asthma. CMAJ. 2010;182(4):E172–E83. Doi: 10.1503/cmaj.071638. With permission.
The principal authors wish to thank Drs Denis Bérubé, Patrick Daigneault, Tom Kovesi, Janet Roberts, Sheldon Spier, David Wensley, Manisha Witmans and Hirotaka Yamashiro, for their expert review and comments during manuscript development. This position statement has been reviewed by the Allergy and Respiratory Health Sections, as well as by the Community Paediatrics and Adolescent Health Committees of the Canadian Paediatric Society.
Members: Adam Cheng MD; Isabelle M Chevalier MD (Board Representative); Catherine A Farrell MD; Jeremy N Friedman MD; Marie Gauthier MD (Board Representative, 2008-2011); Angelo Mikrogianakis MD (Chair); Oliva Ortiz-Alvarez MD
Liaisons: Laurel Chauvin-Kimoff MD, CPS Paediatric Emergency Medicine Section; Marilyn Monk, The Hospital for Sick Children; Jennifer Walton MD, CPS Hospital Paediatrics Section
Principal authors: Oliva Ortiz-Alvarez MD; Angelo Mikrogianakis MD
Disclaimer: The recommendations in this position statement do not indicate an exclusive course of treatment or procedure to be followed. Variations, taking into account individual circumstances, may be appropriate. Internet addresses are current at time of publication.